SecBot SecBot
PRESS-RELEASE ·Filed Mar 11, 2026

LGVN

Longeveron
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ◆ Mixed

The financing alleviates near-term liquidity concerns and funds the critical ELPIS II readout, but the high potential dilution and milestone dependency introduce risk. Traders should monitor the Q3 2026 data readout and any updates on PRV eligibility or second tranche triggers.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.8090
T+0 close · Mar 11, 2026 · via day close
Latest settled
−9.77%
T+60 · $0.7300
Vs SPY
−20.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 12 $0.8090entry
  2. T+1 · 8mo ago +20.40%α +20.99% · $0.9740
  3. T+5 · 8mo ago +37.21%α +38.19% · $1.11
  4. T+20 · 7mo ago +43.39%α +41.41% · $1.16
  5. T+60 · 5mo ago −9.77%α −20.46% · $0.7300
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Longeveron (LGVN) closed the first tranche of a $30 million private placement, raising $15 million upfront through a mix of common and convertible preferred stock issued at $0.52 per share. Proceeds extend the company's cash runway into Q4 2026, covering the pivotal Phase 2b ELPIS II trial readout for HLHS in Q3 2026. An additional $15 million is contingent on clinical milestones and share price performance.

Key Financial Metrics

Deal Value
$15.0M

Key Facts

  • Raised $15 million in initial tranche of private placement, with up to $15 million more contingent on milestones.
  • Issued 6,013,384 Class A common shares and Series A Preferred Shares convertible into 22,832,770 common shares, all priced at $0.52 per share.
  • Cash runway extended into Q4 2026, past the ELPIS II trial topline data readout in Q3 2026.
  • Investors include Coastlands Capital, Janus Henderson Investors, Logos Capital, and Kalehua Capital.
  • Investors receive 50% of proceeds from potential Rare Pediatric Disease Priority Review Voucher (PRV) sale.
  • H.C. Wainwright & Co. acted as exclusive placement agent; registration rights granted for resale.

Financial Impact

$15 million immediate capital raise, with $15 million milestone-dependent. Total potential dilution from conversion: ~28.8 million new shares (478% of current ~6M float).

dilutioncashequityrunway

Risk Factors

  • High dilution: conversion of preferred shares would increase share count by ~478%.
  • Second tranche is not guaranteed, dependent on clinical trial results and share price.
  • No assurance of PRV issuance or monetization, which underpins part of the investor return structure.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3254131

Track record

22 reports on LGVN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
  2. Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
  3. Nov 12, 20264d ago 8-K Bearish 7/10 No price data
  4. Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
  5. Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
  6. Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
  7. Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
  8. Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
  9. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
  10. Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 11, 2026